Ashley Milano  |  May 22, 2015

Category: Legal News

Top Class Actions’s website and social media posts use affiliate links. If you make a purchase using such links, we may receive a commission, but it will not result in any additional charges to you. Please review our Affiliate Link Disclosure for more information.

Xarelto Side Effects Class Action Lawsuit InvestigationBayer is expecting a 30 percent jump in sales of Xarelto this year, even though it faces a growing number of product liability lawsuits involving the anticoagulant. According to the company’s most recent financial release, the medication racked up more than $1 billion in sales during the first quarter of 2015.

“Xarelto expanded its leading position among the new oral anticoagulants, particularly in Europe,” the company’s first quarter financial report states. “Business with Xarelto also developed very positively in the United States, where it is marketed by a subsidiary of Johnson & Johnson.”

Bayer also acknowledged that it has been named a defendant in at least 500 Xarelto injury lawsuits that have been filed in U.S. courts on behalf of individuals who allegedly suffered serious episodes of internal bleeding and other complications due to its use, along with at least five similar Xarelto class action lawsuits in Canada. Additional Xarelto lawsuits are anticipated, according to the company.

What is Xarelto?

Xarelto is a blood thinner that was initially approved by the U.S. Food and Drug Administration (FDA) in July 2011 to prevent strokes in patients who recently underwent hip and knee replacements.

It was also later approved for use in patients with non-valvular atrial fibrillation, or an irregular heartbeat, and to treat or reduce the recurrence of deep vein thrombosis and pulmonary embolism. Since Xarelto was first approved, there have been several reports of bleeding events for those taking Xarelto, including but not limited to, gastrointestinal bleeding, hemmorhagic strokes, and brain hemorrhages.

Xarelto Injury Lawsuits

In December 2014, the Judicial Panel on Multidistrict Litigation (JPML) consolidated all federally-filed Xarelto lawsuits against Janssen Pharmaceuticals, Bayer, and other related entities in a multidistrict litigation in the Eastern District of Louisiana under U.S. District Judge Eldon Fallon.

In the Xarelto bleeding lawsuits that have been filed, some of the allegations include that the manufacturers ignored patient safety and failed to warn about the significant risks with Xarelto, including that in the event of a serious bleeding incident there is no available reversal agent that can be used to stop the bleeding.

It is predicted that several thousand Xarelto injury lawsuits will be consolidated before Judge Fallon, as more Xarelto lawsuits are currently under review.

One of these most recent Xarelto injury lawsuits involves a wrongful death claim filed by an Idaho man on behalf of his deceased wife. Plaintiff Frank P. alleges that his wife, Ann, was prescribed Xarelto in March 2013 and used it as prescribed for approximately one month.

Frank alleges that his wife suffered from internal bleeding, a hemorraghic stroke and eventually died on May 4, 2013 as a result of irreversible Xarelto bleeding.

The Xarelto injury lawsuit claims that Bayer heavily marketed Xarelto by overstating the benefits and understating the risks as a “one-size-fits-all” drug in their advertisements, failing to account for individual patient conditions.

Frank is seeking compensatory and punitive damages and pursuing a wrongful death claim against Xarelto manufacturers, further asserting that the manufacturers over-promoted Xarelto’s benefits compared with its anticoagulant predecessor, warfarin, since Xarelto does not require regular blood monitoring.

Xarelto Bellwether Trials

Parties in the Xarelto MDL have been ordered by Judge Fallon to identify 40 to 60 plaintiffs to go through case-specific discovery and early trial settings. In a case management order on May 4, 2015, the court ordered that parties are to meet prior to June 15, 2015 to propose a process for identifying the Xarelto lawsuits that will be included in a “bellwether” pool.

Bellwether trials are the initial trials in large scale litigation, such as the Xarelto injury lawsuits, and are conducted to help gauge the response of juries to evidence and testimony that may be repeated throughout the litigation.

The Xarelto Bleeding Lawsuit MDL is In Re: Xarelto Products Liability Litigation, MDL No. 2592, in the U.S. District Court for the Eastern District of Louisiana.

Do YOU have a legal claim? Fill out the form on this page now for a free, immediate, and confidential case evaluation. The Xarelto attorneys who work with Top Class Actions will contact you if you qualify to let you know if an individual lawsuit or Xarelto class action lawsuit is best for you. [In general, Xarelto lawsuits are filed individually by each plaintiff and are not class actions.] Hurry — statutes of limitations may apply.

Learn More

Get Help – It’s Free

Join a Free Xarelto Class Action Lawsuit Investigation

If you or a loved one took Xarelto (rivaroxaban) and suffered injuries such as uncontrollable internal bleeding, gastrointestinal bleeding, hemorrhaging, deep vein thrombosis or pulmonary embolism, you may have a legal claim. See if you qualify by filling out the short form below.

An attorney will contact you if you qualify to discuss the details of your potential case at no charge to you.

Oops! We could not locate your form.

We tell you about cash you can claim EVERY WEEK! Sign up for our free newsletter.


Please note: Top Class Actions is not a settlement administrator or law firm. Top Class Actions is a legal news source that reports on class action lawsuits, class action settlements, drug injury lawsuits and product liability lawsuits. Top Class Actions does not process claims and we cannot advise you on the status of any class action settlement claim. You must contact the settlement administrator or your attorney for any updates regarding your claim status, claim form or questions about when payments are expected to be mailed out.